N-Acetyl Epitalon Amidate

Research Use Only. Not for Human Consumption.

N-Acetyl Epitalon Amidate is supplied by Nexus as a terminally modified Epitalon-style AEDG tetrapeptide analog for controlled in-vitro laboratory research workflows. The supplied research record identifies this material as an N-acetylated, C-terminal amidated analog with the displayed sequence Ac-Ala-Glu-Asp-Gly-NH₂. Available Nexus catalog data lists a single 5mg research size under SKU NET5 in the Cognitive & Nootropic category.

Compound Overview

N-Acetyl Epitalon Amidate is described in the supplied chemistry record as a terminally protected analog of the AEDG Epitalon sequence. The parent sequence is AEDG, while the Nexus display sequence is Ac-Ala-Glu-Asp-Gly-NH₂, indicating an N-terminal acetyl group and a C-terminal amide modification. These terminal modifications distinguish the material from an unmodified AEDG tetrapeptide and make terminal-state confirmation an important part of identity review.

The available source data supports a narrow, chemistry-forward description only. No therapeutic, dosing, human-use, veterinary-use, disease-treatment, or biological outcome claims are included in the supplied record, and Nexus does not infer them here. The compound is presented strictly as an in-vitro research material for qualified laboratory settings.

Research Background & Published Literature

The research dataset identifies N-Acetyl Epitalon Amidate as a terminally protected Epitalon-style analog used in stability and peptide-modification research contexts. The provided source list includes a PubChem record for the parent Epitalon/AEDG sequence and a supplier PDF for N-acetyl Epithalon amidate. The supplied research record does not include peer-reviewed citations specific to this exact terminally modified analog.

• Parent sequence context: Epitalon-style AEDG tetrapeptide sequence.
• Analog description: N-acetylated, C-terminal amidated AEDG analog.
• Literature limitation: No peer-reviewed citations specific to N-Acetyl Epitalon Amidate were provided in the supplied dataset.
• Verification limitation: Terminal modification state should be confirmed by COA/MS before relying on computed formula values as final release specifications.

Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:

• Khavinson VKh et al. (2003) — Bull Exp Biol Med
• Khavinson et al. (2017) — Bull Exp Biol Med
• Araj et al. (2025) — Int J Mol Sci

Storage, Handling & Stability Guidelines

Use the applicable lot/source record for storage of unopened material. Any diluent selection, preparation, temperature, aliquoting, or post-reconstitution hold conditions must be established by a qualified laboratory under a validated SOP; this page does not establish a stability window.

• Keep lyophilized material sealed, dry, and light-protected during storage.
• Maintain -20°C storage conditions for the unreconstituted material unless a current COA specifies otherwise.
• Use a validated laboratory SOP and the applicable lot/source record for any preparation or post-reconstitution handling.
• Do not infer a beyond-use date, reconstitution solvent, or working concentration from this page; those parameters are not supplied in the research data.

Quality Assurance & Lab Verification

The Certificate of Analysis for this catalog item is pending. No provisional batch, assay, method, analyst, or release data is published in this product dossier. Check the Lab Verified archive for documentation status.